NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02322593,Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer,https://clinicaltrials.gov/study/NCT02322593,SOLAR,COMPLETED,The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.,YES,Gastric Cancer,DRUG: TAS-118 plus Oxaliplatin|DRUG: S-1 plus Cisplatin,"Overall Survival, The primary endpoint was OS, which was defined as the time from the date of randomization to the date of death from any cause. Surviving patients were censored at the cutoff date or last contact date if lost to follow-up, or upon withdrawal of consent., A survival follow-up was required every 12 weeks from the date of randomization to the date of death from any cause, whichever came first, assessed up to 38 months.","Progression-free Survival, PFS was defined as the time from the date of randomization to the date of disease progression (assessed by each investigator) or death from any cause, whichever came first., A radiographic imaging examination using CT or MRI was repeated every 6 weeks. Tumor assessments were performed from the date of randomization to the date of disease progression or death from any cause, whichever came first.|Time to Treatment Failure, TTF was defined as the time from the date of randomization to the date of the last administration of the study drug. Patients on study treatment were censored at the date of the last administration or the cutoff date, whichever came earlier., From the date of randomization to the date of the last administration of the study drug.|Overall Response Rate, ORR was defined as the proportion of patients with the best unconfirmed overall response of complete response (CR) or partial response (PR) in patients with measurable lesions, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months.|Disease Control Rate, DCR was defined as the proportion of patients with CR, PR, or stable disease in patients with measurable lesions., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months.",,"Taiho Pharmaceutical Co., Ltd.","Yakult Honsha Co., LTD",ALL,"ADULT, OLDER_ADULT",PHASE3,711,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,10056040,2014-12,2019-02,2020-05,2014-12-23,2021-12-20,2021-12-20,"Taiho Pharmaceutical Co., Ltd selected site, Ibaraki, 305-8576, Japan|Taiho Pharmaceutical Co., Ltd selected site, Kumamoto, 860-8556, Japan|Taiho Pharmaceutical Co., Ltd selected site, Tokyo, 104-0045, Japan|Taiho Pharmaceutical Co., Ltd selected site, Seoul, 110-744, Korea, Republic of|Taiho Pharmaceutical Co., Ltd selected site, Seoul, 120-752, Korea, Republic of|Taiho Pharmaceutical Co., Ltd selected site, Seoul, 138-736, Korea, Republic of","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/93/NCT02322593/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/93/NCT02322593/SAP_001.pdf"
